May 2026– date –
-
Japan: AMCHEPRY® for Parkinson’s (~$350,600) and RiHEART® for Severe Heart Failure (~$63,500+) iPSC Cell Therapies Show Positive Early Clinical Results in 7 Patients
Reddit (r/stemcells) Japan Overview Early clinical trials for Japan-originated iPSC cell therapies, AMCHEPRY® for Parkinson's disease and RiHEART® for severe ischemic heart failure, have shown positive results in a total of seven patient... -
Allogene Therapeutics’ Anti-B7-H3 Allogeneic CAR γδ T Cell Therapy QH104 Shows Favorable Safety, Disease Stabilization in Leptomeningeal Metastasis Phase 1 Trial
PubMed USA Overview Allogene Therapeutics' anti-B7-H3 allogeneic CAR γδ T cell therapy, QH104, demonstrated a favorable safety profile and promising efficacy in a Phase 1 clinical trial for patients with leptomeningeal metastasis (LM) fr... -
Europe’s Biotech Vanguard: Ori Biotech’s Modular Automation Reshapes Cell and Gene Therapy Manufacturing
PharmTech ヨーロッパ Overview European biotechnology firms are pioneering advanced manufacturing solutions to overcome critical production hurdles in cell and gene therapies. Ori Biotech, in strategic collaborations with Cell Therapies, ... -
Genprex’s Reqorsa® Gene Therapy Extends Progression-Free Survival in NSCLC Patients with High Trop-2/Low PTEN Biomarkers, ASCO 2026 Data Shows
Genprex, Inc. USA Overview Genprex, Inc. presented positive clinical data on predictive biomarkers for its Reqorsa® gene therapy in non-small cell lung cancer (NSCLC) patients at the 2026 ASCO Annual Meeting. The data indicates that pati... -
CELLINK’s 3D Bioprinting Expands Organoid Production, Accelerating Drug Discovery and Regenerative Medicine
ATCG India India Overview CELLINK's 3D bioprinting technology is driving the future of cell culture by providing innovative solutions to support research in cultivated meat, tissue engineering, and regenerative medicine. Integrating orga... -
Cynata Therapeutics Anticipates Announcing iPSC-MSC Clinical Results for Knee Osteoarthritis Phase 3 and Acute GvHD Phase 2 Trials Soon
Regen Report Australia Overview Australian cell therapy company Cynata Therapeutics has announced it will release results from two pivotal clinical trials using its iPSC-derived mesenchymal stem cells (iPSC-MSC) within months. These incl... -
Exosome Therapy Shows Promising Early Clinical Results for Skin Rejuvenation and Hair Loss Treatment, Facing Regulatory Approval Challenges
Skin Therapy Letter USA Overview Exosome therapy, functioning as an intercellular messenger carrying stem cell-derived growth factors and proteins, demonstrates promising early clinical results in both skin rejuvenation and hair loss tre... -
Health Canada Accepts Vertex Pharmaceuticals’ New Drug Submission for Suzetrigine, a Novel NaV1.8 Inhibitor, for Moderate-to-Severe Acute Pain in Adults
BioSpace (via CNW) Canada Overview Vertex Pharmaceuticals announced that Health Canada has accepted its New Drug Submission (NDS) for suzetrigine, a novel oral NaV1.8 selective pain signal inhibitor, for the treatment of moderate-to-seve... -
Intellia Therapeutics Bolsters Market Value with Soaring Stock Price and Improved Financials Amid Positive CRISPR Gene Editing Regulatory Progress
Fintel USA Overview Intellia Therapeutics saw its stock price climb to $12.60 per share, marking a 35.12% year-over-year increase by May 2026, boosting its market capitalization to $1.91 billion. The company also improved its net loss in... -
UCLH Pioneering Gene Editing Therapy Successfully Lowers ‘Bad’ Cholesterol (LDL-C) with Single Dose in Encouraging Early Clinical Trial
University College London Hospitals NHS Foundation Trust UK Overview An early-stage clinical trial at University College London Hospitals (UCLH) has shown promising results where a single dose of gene editing therapy significantly lowere...
